Evidence map›Paper›PMID 33320412›Full record

ReviewBipolar disorders2020

The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary.

Gin S Malhi, Erica Bell, Ajeet B Singh, Darryl Bassett, Michael Berk, Philip Boyce, Richard Bryant, Michael Gitlin, Amber Hamilton, Philip Hazell and 9 more

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Bipolar disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Korean Medication Algorithm for Depressive Disorder 2025, Fifth Revision: An Executive Summary.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Effectiveness of Buspirone in Alleviating Anxiety Symptoms in Patients with Depressive Disorder: A Multicenter Prospective Observational Study in Korea.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Article
  15. Is there a risk of esketamine misuse in clinical practice?Therapeutic advances in drug safety · 2025
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 5 countries.

Gin S MalhiDepartment of Psychiatry, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-4524-9091
Erica BellDepartment of Psychiatry, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-8483-8497
Ajeet B SinghThe Geelong Clinic Healthscope, IMPACT - Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, VIC, Australia.ORCID 0000-0002-0853-7959
Darryl BassettConsultant Psychiatrist, Perth, WA, Australia.
Michael BerkIMPACT - the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia.ORCID 0000-0002-5554-6946
Philip BoyceDepartment of Psychiatry, Westmead Hospital and the Westmead Clinical School, Wentworthville, NSW, Australia.ORCID 0000-0002-9816-7356
Richard BryantSchool of Psychology, University of New South Wales, Sydney, NSW, Australia.ORCID 0000-0002-9607-819X
Michael GitlinDepartment of Psychiatry, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID 0000-0001-7236-9649
Amber HamiltonDepartment of Psychiatry, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.ORCID 0000-0001-9001-4585
Philip HazellDiscipline of Psychiatry, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-8085-2996
Malcolm HopwoodDepartment of Psychiatry, University of Melbourne and Professorial Psychiatry Unit, Albert Road Clinic, Melbourne, Vic., Australia.ORCID 0000-0001-6004-4521
Bill LyndonDepartment of Psychiatry, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Roger S McIntyreMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.ORCID 0000-0003-4733-2523
Grace MorrisDepartment of Psychiatry, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.ORCID 0000-0003-3598-9712
Roger MulderDepartment of Psychological Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0002-8147-5838
Richard PorterDepartment of Psychological Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0002-8695-3966
Lakshmi N YathamDepartment of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-7405-0954
Allan YoungDepartment of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
Greg MurrayCentre for Mental Health, Swinburne University of Technology, Hawthorn, VIC, Australia.ORCID 0000-0001-7208-5603
The University of Sydney · AUUniversity of Otago · NZBarwon Health · AUDeakin University · AUKing's College London · GBRoyal College of Psychiatrists · GBSwinburne University of Technology · AUThe University of Melbourne · AUUniversity Health Network · CAUniversity of British Columbia · CAUniversity of California, Los Angeles · USUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo provide a succinct, clinically useful summary of the management of major depression, based on the 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (MDcpg

methodsTo develop the MDcpg

resultsThe depression summary provides a systematic approach to diagnosis, and a logical clinical framework for management. The latter begins with Actions, which include important strategies that should be implemented from the outset. These include lifestyle changes, psychoeducation and psychological interventions. The summary advocates the use of antidepressants in the management of depression as Choices and nominates seven medications that can be trialled as clinically indicated before moving to Alternatives for managing depression. Subsequent strategies regarding Medication include Increasing Dose, Augmenting and Switching (MIDAS). The summary also recommends the use of electroconvulsive therapy (ECT), and discusses how to approach non-response.

conclusionsThe major depression summary provides up to date guidance regarding the management of major depressive disorder, as set out in the MDcpg

Indexed as

Practice Guidelines as TopicPsychiatryAntidepressive AgentsAustraliaConsensusElectroconvulsive TherapyHumansMajor Depressive DisorderMood DisordersNew ZealandSocieties, MedicalAntidepressive Agentsdepressionguidelinemood disorderstreatment

Identifiers

PMID33320412
OpenAlexW3110932765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.